Recent data suggest an interaction between the renin-angiotensinaldosterone system and fibrinolysis. Although previous work has focused on the effect of angiotensin II (Ang II) on plasminogen activator inhibitor (PAI-1) expression, the present study tests the hypothesis that aldosterone contributes to the regulation of PAI-1 expression. To test this hypothesis in vitro, luciferase reporter constructs containing the human PAI-1 promoter were transfected into rat aortic smooth muscle cells. Exposure of the cells to 100 nmol/L Ang II resulted in a 3-fold increase in luciferase activity. Neither 1 mol/L dexamethasone nor 1 mol/L aldosterone alone increased PAI-1 expression. However, both dexamethasone and aldosterone enhanced the effect of Ang II in a dose-dependent manner. This effect was abolished by mutation in the region of a putative glucocorticoid-responsive element. A similar interactive effect of Ang II and aldosterone was observed in cultured human umbilical vein endothelial cells. The time course of the effect of aldosterone on Ang II-induced PAI-1 expression was consistent with a classical mineralocorticoid receptor mechanism, and the effect of aldosterone on PAI-1 synthesis was attenuated by spironolactone. To determine whether aldosterone affected PAI-1 expression in vivo, we measured local venous PAI-1 antigen concentrations in six patients with primary hyperaldosteronism undergoing selective adrenal vein sampling. PAI-1 antigen, but not tissue plasminogen activator antigen, concentrations were significantly higher in adrenal venous blood than in peripheral venous blood. Taken together, these data support the hypothesis that aldosterone modulates the effect of Ang II on PAI-1 expression in vitro and in vivo in humans. (J Clin Endocrinol Metab 85: 336 -344, 2000) A CTIVATION of the renin-angiotensin-aldosterone system (RAAS) has been associated with an increased risk of ischemic cardiovascular events, independent of effects on blood pressure (1, 2). Conversely, interruption of the RAAS by angiotensin-converting enzyme (ACE) inhibition reduces cardiovascular mortality in patients with left ventricular dysfunction (3, 4). The mechanisms underlying these effects are not well understood. We have previously proposed that a major component of the vascular toxicity associated with activation of the RAAS is derived from the effects of angiotensin II (Ang II) on fibrinolytic balance (5, 6). Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis in vivo (7), and increased PAI-1 expression has been observed in atherosclerotic plaque (8, 9). Elevated levels of PAI-1 are seen in youthful survivors of acute myocardial infarction (MI) compared with age-matched controls (10), and appear to be a risk factor for recurrent MI in this cohort (11). Similarly, elevated PAI-1 activity is associated with increased risk of cardiovascular death in patients with unstable angina (12). In addition, by preventing the activation of matrix metalloproteinases by plasmin (13), PAI-1 promotes fibrosis (14). Ang II causes a dosedependent increase in PAI-1 expression in vitro and in vivo (5, 15). Interruption of the RAAS by ACE inhibition decreases PAI-1 concentrations in salt-deplete normotensive subjects (16), hypertensive subjects (17), and post-MI patients (18).
A CTIVATION of the renin-angiotensin-aldosterone system (RAAS) has been associated with an increased risk of ischemic cardiovascular events, independent of effects on blood pressure (1, 2) . Conversely, interruption of the RAAS by angiotensin-converting enzyme (ACE) inhibition reduces cardiovascular mortality in patients with left ventricular dysfunction (3, 4) . The mechanisms underlying these effects are not well understood. We have previously proposed that a major component of the vascular toxicity associated with activation of the RAAS is derived from the effects of angiotensin II (Ang II) on fibrinolytic balance (5, 6) . Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of fibrinolysis in vivo (7) , and increased PAI-1 expression has been observed in atherosclerotic plaque (8, 9) . Elevated levels of PAI-1 are seen in youthful survivors of acute myocardial infarction (MI) compared with age-matched controls (10) , and appear to be a risk factor for recurrent MI in this cohort (11) . Similarly, elevated PAI-1 activity is associated with increased risk of cardiovascular death in patients with unstable angina (12) . In addition, by preventing the activation of matrix metalloproteinases by plasmin (13) , PAI-1 promotes fibrosis (14) . Ang II causes a dosedependent increase in PAI-1 expression in vitro and in vivo (5, 15) . Interruption of the RAAS by ACE inhibition decreases PAI-1 concentrations in salt-deplete normotensive subjects (16) , hypertensive subjects (17) , and post-MI patients (18) .
In salt-deplete normotensive subjects, we observed that plasma PAI-1 concentrations correlate significantly with aldosterone concentrations (16) . One possible explanation for this correlation is that Ang II increases the synthesis of both aldosterone (19) and PAI-1 (5, 6) . However, the identification of a glucocorticoid-responsive element (GRE) in the promoter of the PAI-1 gene (20) and the observation that glucocorticoids increase PAI-1 expression in cultured cells (20 -27) suggest an alternative hypothesis that the mineralocorticoid aldosterone also regulates PAI-1 expression. The present study tests this hypothesis both in vitro and in vivo. To test this hypothesis in vitro, we examined the effect of the glucocorticoid dexamethasone and the mineralocorticoid aldosterone on PAI-1 expression in rat aortic smooth muscle (RASM) cells transfected with a series of luciferase reporter constructs containing variable lengths of the human PAI-1 promoter. To test the hypothesis in humans, we measured local plasma PAI-1 antigen concentrations in patients with primary hyperaldosteronism who were undergoing selective adrenal vein sampling. 
Materials and Methods

Cell culture
RASM cells were isolated as previously described (28) . Cells were maintained in DMEM with 10% FBS, penicillin (100 U/mL), streptomycin (100 g/mL), and 25 mmol/L HEPES. For these studies, RASM cells were subcultured 10 -16 times. The cells were identified as smooth muscle cells by both appearance and positive fibrillar staining with a smooth muscle-specific ␣-actin antibody (Roche Molecular Biochemicals, Mannheim, Germany). Human umbilical vein endothelial cells (HUVECs) were propagated from pooled primary cultures of human umbilical veins as previously described (29) . HUVECs were grown on gelatin-coated plates in DMEM containing 25 mmol/L HEPES buffer and 2.0 mmol/L glutamine supplemented with 20% FBS, 50 g/mL endothelial mitogen, 50 U/mL penicillin, and 50 g/mL streptomycin. Cells subcultured fewer than three times were used in these experiments. HUVECs were grown to confluence in 100-mm tissue culture dishes, washed twice with sterile PBS, and then incubated overnight with serum-free DMEM.
Reporter constructs
PAI-1-luciferase reporter vectors were constructed by cloning various portions of the PAI-1 promoter into the pGL2-Basic luciferase vector (Promega Corp.) as previously described (30) . The original promoter construct (Ϫ6.4 kbp) of the PAI-1 promoter was provided by Dr. David J. Loskutoff (Scripps Research Institute, La Jolla, CA).
Site-directed mutagenesis
Base substitutions were made by oligonucleotide-mediated mutagenesis in the region identified P-box, corresponding to nucleotides Ϫ71 to Ϫ47 (Fig. 1) . The mutant oligonucleotides used as primers are illustrated in Fig. 1 together with the corresponding wild-type PAI-1 sequence. The mutations were made with Altered Sites in vitro mutagenesis kit (Promega Corp.). Mutation accuracy was checked by restriction enzyme mapping and direct sequencing.
Transfection assay
For transient transfection experiments, RASM cells were cultured in 35-mm six-well plates at density of 1 ϫ 10 5 cells/well. After cells reached 70 -80% confluence, they were transfected using the diethylaminoethyldextran method (31) with 1 g of the PAI-1 pGL-2 construct and 0.8 g of the plasmid pMVS-␤-Gal, which contains the lacZ gene under control of the Moloney sarcoma virus long terminal repeat. The control plasmid has been examined on several occasions and has never demonstrated any response to Ang II (data not shown). After overnight incubation, the medium was replaced with serum starvation medium (5.5 mmol/L glucose, DMEM containing 5 ϫ 10 Ϫ7 mol/L insulin, 5 g/mL transferrin, and 0.2 mmol/L ascorbic acid) supplemented with aldosterone or dexamethasone for 24 h. The following morning, the cells were then kept in glucose-deficient DMEM supplemented with Ang II and or/dexamethasone or aldosterone. After 6 h, the cells were harvested with reporter lysis buffer. The luciferase assays were performed according to the protocol of Promega Corp. A 50-L sample of the extract was used for determination of ␤-galactosidase activity by colorimetric assay (32) . The luciferase activity was corrected for ␤-galactosidase activity and is presented as corrected light units.
Northern blot analysis
For the Northern blot analysis, cells were grown in 100-mm tissue culture dishes. When the cells reached 80% confluence, the cells were then kept in the DMEM supplemented with different concentrations of Ang II, aldosterone, dexamethasone, and spironolactone. In all studies in RASM, the duration of agonist exposure was 6 h. In HUVECs the effect of time on aldosterone-induced PAI-1 expression was determined by varying the duration of aldosterone exposure: 0.5, 1, 2, 4, 6, 8, and 24 h. In addition, studies were performed in the presence of 5 mol/L actinomycin D. Total cellular ribonucleic acid (RNA) isolation and Northern blot analysis were carried out as previously described (6) . For PAI-1 antigen measurements, conditioned media were collected, centrifuged to remove cellular debris, and stored at Ϫ70 C until assays were performed.
Human subjects
Six consecutive patients with biochemical evidence of primary hyperaldosteronism who had been referred for adrenal vein sampling were asked to participate in the study. Biochemical evidence was defined as failure of serum aldosterone to suppress to less than 10 ng/dL after iv infusion of 1.5 L normal saline or 24-h urinary aldosterone excretion greater than 17 g/24 h. Baseline aldosterone concentration and PRA were 41.4 Ϯ 10.7 (range, 20.4 -86) ng/dL and 0.41 Ϯ 0.08 (range, 0.2-0.66) ng Ang I/mL⅐h, respectively. Three of the six patients had a single adrenal nodule by computed tomography scan, and two others had generalized enlargement of one adrenal gland. All patients had been off spironolactone for at least 3 weeks before adrenal vein sampling and were taking potassium supplementation to maintain normokalemia. All patients gave informed consent for the collection of blood for measurement of PAI-1 and tissue plasminogen activator (t-PA) antigen, in addition to aldosterone and cortisol concentrations, at each site. The consent form was approved by the Vanderbilt University institutional review board.
Adrenal vein sampling procedure
Adrenal vein sampling was performed in the morning in all but one patient. The right groin was prepped and draped in a sterile fashion. Lidocaine was administered as a local anesthetic. Using a Seldinger technique the right common femoral vein was punctured, and a wire was advanced into the inferior vena cava (IVC). A catheter was advanced into the left renal vein and pulled back to engage the orifice of the left adrenal vein, and blood samples were obtained. A second catheter was then used to select the right adrenal vein and obtain samples. In some of the cases, a small amount of contrast was injected to confirm catheter placement. After adrenal vein sampling, blood samples were obtained from the IVC. The total duration of each study was less than 1 h.
Laboratory analysis
Blood samples were collected on ice and centrifuged at 0 C for 20 min. All plasma or serum was separated and stored at Ϫ70 C until the time of assay. Blood for measurement of PAI-1 and t-PA was collected in standard Vacutainer tubes containing 0.105 mol/L sodium citrate (Becton Dickinson and Co., Rutherford, NJ) to prevent release of platelet PAI-1. PAI-1 and t-PA antigen levels were determined using a two-site enzyme-linked immunosorbent assay (Biopool AB, Umea, Sweden) as previously described (15) . In our laboratory, the coefficients of variation for repeated measures of t-PA antigen and PAI-1 antigen are 5.9% and 8.1%, respectively. Blood for PRA was collected in tubes containing ethylenediamine tetraacetate. PRA was measured by RIA for Ang I formation at pH 7.4 and 37 C (33). Serum aldosterone and cortisol were assayed using a commercially available RIA kits. For aldosterone (Diagnostic Products, Los Angeles, CA) the intra-and interassay coefficients of variation were 6% and 10%, respectively. For cortisol (INC-STAR Corp., Stillwater, MN), the intra-and interassay coefficients of variation were 4.5% and 6.7%, respectively.
Statistical analysis
The effects of hormones on PAI-1 expression, as measured by luciferase activity, were compared using unpaired t test or Mann-Whitney test, as appropriate. The dose effect of dexamethasone or aldosterone was determined by one-way ANOVA followed by Bonferroni correction for multiple comparisons. In patients with hyperaldosteronism, comparison between IVC and adrenal vein was made using paired t test or Wilcoxon signed ranks test, as appropriate. All P values are two-sided. P Ͻ 0.05 was judged to be significant.
Results
Effect of dexamethasone and aldosterone on PAI-1 expression in transfected rat aortic smooth muscle cells and in human umbilical vein endothelial cells
To determine whether dexamethasone and aldosterone regulate PAI-1 gene expression, we measured the effects of these steroids on luciferase activity in RASM transiently transfected with constructs containing a 3-kb portion of the human PAI-1 promoter and 72 nucleotides of the PAI-1 5Ј-untranslated region fused to a luciferase reporter gene (Figs. 2 and 3). Neither 1 mol/L dexamethasone alone nor 1 mol/L aldosterone alone increased luciferase activity compared to the control value (Fig. 2) . Ang II (100 nmol/L, a concentration previously shown to maximally stimulate PAI-1 expression) increased luciferase activity 3-fold compared to the control value. However, in the presence of 100 nmol/L Ang II, both dexamethasone (effect of dose: F ϭ 7.8; P ϭ 0.022) and aldosterone (effect of dose: F ϭ 40.4; P Ͻ 0.001) caused a concentration-dependent increase in PAI-1 expression (Fig. 3) . To determine whether the effect of aldosterone on PAI-1 gene expression was cell or species specific, the relative expression of PAI-1 messenger RNA (mRNA) in HUVECs was measured by Northern blotting and phosphorimaging (Fig. 4) . In these experiments, aldosterone enhanced the effect of Ang II on PAI-1 expression in a concentration-dependent manner. Enhancement of PAI-1 expression was seen after 6 -8 h of exposure to aldosterone but not after shorter exposure. Treatment with 5 mol/L actinomycin D blocked the effect of aldosterone on PAI-1 mRNA expression (data not shown). The effect of aldosterone on PAI-1 expression (not shown) and protein synthesis (Fig. 4) was attenuated by an excess concentration (10 mol/L) of the mineralocorticoid receptor antagonist spironolactone.
Mapping of the steroid-responsive element in the PAI-1 promoter
To localize the regulatory elements required for transcriptional activation of the PAI-1 gene by dexamethasone and aldosterone, progressive 5Ј-promoter deletion constructs containing different portions of the PAI-1 promoter and 72 nucleotides of the PAI-1 5Ј-untranslated region were fused to a luciferase reporter gene construct. In addition, site-directed mutagenesis was performed on the sequence from Ϫ71 to Ϫ47 to introduce an EcoRI restriction site in a P-box, localized close to the glucocorticoid-responsive element (Fig. 1) . In the longer constructs, aldosterone and dexamethasone acted synergistically with Ang II to increase PAI-1 expression (Fig.  2) . Thus, relative luciferase expression during combined steroid/Ang II administration was significantly greater than that during either steroid alone plus that during Ang II alone (e.g. P ϭ 0.04 for relative luciferase activity measured during combined treatment with aldosterone and Ang II vs. that measured during aldosterone alone plus that measured during Ang II alone for the 1.3-kb construct). In the 884-and 107-bp constructs, the effects of aldosterone and dexamethasone were additive to the effect of Ang II. However, mutation of the P-box abolished the effect of either steroid on PAI-1 expression. This result supports the involvement of the nearby glucocorticoid-responsive element in dexamethasone and aldosterone activation of the PAI-1 gene.
FIG. 2.
Induction of luciferase activity with Ang II and/or dexamethasone or aldosterone in RASM cells transfected with PAI-1 promoter/luciferase reporter gene constructs. Results represent the mean Ϯ SE of at least four independent experiments. *, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.005 (vs. controls). ϩ, P Ͻ 0.05; ϩϩ, P Ͻ 0.01; ϩϩϩ, P Ͻ 0.005 (vs. Ang II alone). Table 1 lists local venous aldosterone and cortisol concentrations in the six patients who underwent adrenal vein sampling. In several patients there was difficulty cannulating the right adrenal vein. Samples were judged to have been successfully obtained from the right adrenal vein if there was a step-up in cortisol concentration compared to the concentration in the IVC (Table 1) . However, comparison of cortisol concentrations in the right and left adrenal veins suggests that incomplete cannulation of the right adrenal vein was common. In two patients, aldosterone hypersecretion lateralized to one adrenal gland (cases 3 and 5); thus, the aldosterone/cortisol ratio was significantly higher in blood obtained from the right adrenal vein compared to that obtained from the left adrenal vein or the IVC in both patients. The concentrations of both cortisol (by definition) and aldosterone were significantly higher in either adrenal vein compared to those in the IVC (Fig. 5) . Table 2 shows local venous PAI-1 antigen and t-PA antigen concentrations in the six patients. No sample was obtained from the right adrenal vein in two of the patients (cases 1 and 4). PAI-1 antigen concentrations measured in either adrenal vein were significantly higher compared to concentrations in the IVC (P ϭ 0.007; Fig. 6 ). In contrast, there was no difference in t-PA antigen concentrations between the IVC and the adrenal veins. To assess specifically the effect of aldosterone production on PAI-1 antigen, we examined the relationship between local aldosterone concentrations and PAI-1 concentrations within each patient. In the two patients in whom aldosterone hypersecretion lateralized to one side, and thus in whom there was a range of aldosterone concentrations, local PAI-1 antigen concentrations correlated significantly with aldosterone concentrations in case 3 (P ϭ 0.013), but not in case 5 (P ϭ 0.17; Fig. 7) . The relationship between PAI-1 antigen concentrations and cortisol concentrations was not significant in either of these patients. Interindividual variation in PAI-1 antigen concentrations made it difficult to measure the relationship between aldosterone and PAI-1 across patients. To control for this, local venous PAI-1 antigen concentrations were normalized to IVC PAI-1 antigen concentrations within the same individual. There was a significant correlation between normalized PAI-1 antigen and the aldosterone/cortisol ratio (r 2 ϭ 0.5; P ϭ 7 ϫ 10 Ϫ4 ) in venous samples from all six patients combined.
Adrenal vein sampling
Discussion
Numerous previous studies have demonstrated that glucocorticoids enhance PAI-1 expression in cultured cells such as human fibroblasts (23), fibrosarcoma cells, (24) , mammary carcinoma cells (25) , and both rat and human hepatoma cells (22, 26, 27) . The present study tests the hypothesis that the mineralocorticoid aldosterone also regulates PAI-1 expression. The data obtained in transfected RASM cells suggest that although neither dexamethasone nor aldosterone alone stimulates PAI-1 expression, both dexamethasone and aldosterone interact synergistically with Ang II to increase PAI-1 expression. Moreover, in both transfected RASMs and HUVECs, the effects of dexamethasone and aldosterone were concentration dependent. The concentration of aldosterone associated with increased PAI-1 expression in transfected RASMs (Ն50 nmol/L) is approximately 10-fold higher than that measured in peripheral venous blood, but is comparable to concentrations measured in the adrenal vein. On the other hand, aldosterone induced PAI-1 expression in HUVECs at physiological concentrations.
The mechanism for the interactive effect of Ang II and steroids on PAI-1 expression is not addressed in the present study. One possible mechanism involves an effect of the steroids on Ang II receptor expression. Previous studies in VSMCs and rat aortic rings suggest that aldosterone and corticosterone increase Ang II-stimulated contractions through up-regulation of AT 1 receptor binding (34, 35) . However, although in VSMCs the effect of Ang II on PAI-1 expression appears to be mediated through the AT 1 receptor (36), in endothelial cells the effect of Ang II on PAI-1 expression is mediated through the AT 4 receptor (6). Thus, studies are needed to determine the effects of dexamethasone and aldosterone on Ang II binding and on the Ang II concentration-PAI-1 response curves in specific cell types.
Corticosteroids such as dexamethasone and aldosterone bind to intracellular type I receptors (37) . Although aldosterone binds to the mineralocorticoid receptor with relative specificity, glucocorticoids bind to both the mineralocorticoid and glucocorticoid receptors (38) . In vivo, mineralocorticoid specificity is maintained by conversion of cortisol to its inactive metabolite cortisone by 11␤-hydroxysteroid dehydrogenase (11␤HSD). In culture, VSMCs express mRNA of Table 1 . the type 1 isoform, whereas endothelial cells express both type 1 and type 2 isoforms of 11␤-hydroxysteroid dehydrogenase (39) Because dexamethasone is a poor substrate for the type 1 isoform (40), it is possible that both dexamethasone and aldosterone were acting through a mineralocorticoid receptor in the present experiments. After translocation, ligand-activated mineralocorticoid or glucocorticoid receptors bind to hormone response elements in the regulatory region of target gene promoters and mediate transcriptional activity (38) . In the present study, inhibition of transcription with actinomycin D blocked the effect of aldosterone on PAI-1 expression. In addition to binding to a nuclear receptor, aldosterone appears to alter electrolyte fluxes in a number of cell types through rapid interaction with a nongenomic receptor (41) . In the present study, the time course of the effect of aldosterone on PAI-1 expression and the finding that this effect is attenuated by spironolactone suggest that aldosterone induces PAI-1 expression and synthesis through a classical mineralocorticoid receptor pathway.
Based on functional studies, van Zonneveld et al. have identified two GREs within the human PAI-1 promoter, one located between positions Ϫ100 and ϩ75 and a second region in the promoter located between nucleotides Ϫ800 and Ϫ549 (20) . These investigators identified a sequence at position Ϫ64 to Ϫ59 whose complementary strand (5Ј-TGTTCC-3Ј) resembles one half of a GRE (20) . Data from the present study suggest that the effect of either dexamethasone or aldosterone on PAI-1 expression requires interaction with the GRE located between Ϫ100 and ϩ75, as mutations in the region (107 mPbox) abolished the effect of either steroid on PAI-1 expression. However, we cannot exclude the possibility that the mutations introduced at Ϫ57 and Ϫ59 to Ϫ61 could have altered the function of a putative Ang-responsive element at Ϫ48 to Ϫ38 (42), particularly as the mutations reduced the response to Ang II alone. The loss of synergy between Ang II and steroids with truncation of the PAI-1 promoter from 1.3 kb to 884 bp is compatible with the existence of a second GRE upstream.
This study is the first to examine the effects of adrenal steroids on PAI-1 synthesis in humans. To do this we adopted a strategy of measuring local plasma PAI-1 concentrations in patients undergoing selective adrenal vein sampling. Because each subject served as his own control and because samples were obtained within a narrow period of time, confounding factors, such as salt intake (16) , medication use (16) , and glucose and insulin concentrations (43, 44) , were held constant within subject. The results of the study suggest that in humans, as we observed in vitro, adrenal steroids influence PAI-1 production. Thus, PAI-1 antigen concentrations were 25% higher in samples obtained from the adrenal veins compared to concentrations in the IVC. In contrast, t-PA antigen concentrations were similar in the adrenal veins and IVC. In vivo, the effect of adrenal steroids on PAI-1, although significant, appears to be modest; this may reflect the importance of a number of other neurohumoral factors, such as Ang II (5, 6), renin (45) , and glucose and insulin (30, 43, 44) on the regulation of PAI-1 synthesis. In particular, if as suggested in vitro, aldosterone interacts with Ang II to increase PAI-1 expression, suppressed renin activity and Ang II in patients with primary hyperaldosteronism may attenuate the effect of aldosterone.
One of the limitations of the adrenal vein sampling study is that the results do not allow us to distinguish with certainty between the effects of cortisol and aldosterone on PAI-1 synthesis. In only two patients did aldosterone hypersecretion lateralize to one adrenal gland. This relates in part to difficulty sampling from the right adrenal vein. Nevertheless, the relationship between local aldosterone and PAI-1 concentrations in one of these patients together with the correlation between normalized PAI-1 and the aldosterone/ cortisol ratio in all patients combined suggest that, as we observed in vitro, aldosterone regulates PAI-1 synthesis in Table 2 .
humans. The present study also does not allow us to exclude the hypothesis that adrenal products other than aldosterone or cortisol increase PAI-1 expression. Catecholamines do not appear to alter PAI-1 concentrations in humans (46, 47) ; however, other factors present in adrenal venous blood could conceivably alter PAI-1 expression. In addition, the present study does not address the cell source of PAI-1 measured in the adrenal vein. The findings that the mineralocorticoid aldosterone increases PAI-1 expression in cultured cells and that PAI-1 antigen concentrations are increased in adrenal venous blood in humans have significant clinical implications. Emerging data indicate that aldosterone causes myocardial (48), vascular (49) , and renal fibrosis (50) in animal models and that hyperaldosteronism is associated with vascular dysfunction in humans (51) . Because PAI-1 plays a role in the regulation of fibrosis (14) , increased PAI-1 expression could contribute to the fibrotic effects of aldosterone. Given data suggesting that aldosterone is produced locally in the vasculature (52) , aldosterone may exert an autocrine or paracrine effect on fibrinolysis. High concentrations of aldosterone observed in obese, hypertensive, insulin-resistant patients (53) could contribute to the increased PAI-1 concentrations observed in this population (54) . Perhaps most importantly, although ACE inhibitors have been shown to lower mortality due to myocardial ischemia in patients with left ventricular dysfunction (3, 4), aldosterone concentrations have been dem- FIG. 7 . Relationship between local plasma PAI-1 concentration and serum aldosterone concentrations in six patients with hyperaldosteronism. In case 3, there was a statistically significant relationship between PAI-1 and aldosterone (P ϭ 0.013), but not between PAI-1 and cortisol (P ϭ 0.1).
onstrated to return toward baseline or escape during chronic ACE inhibition (55) . Recently, coadministration of an aldosterone antagonist (56) has been shown to reduce mortality 26% in heart failure patients treated with ACE inhibitor. The results of the present study suggest a possible mechanism for this favorable effect of aldosterone receptor antagonism; however, studies of the effect of aldosterone antagonists on fibrinolytic balance are needed to test this hypothesis.
In summary, this study demonstrates that both glucocorticoids and mineralocorticoids interact synergistically and in a concentration-dependent fashion with Ang II to enhance PAI-1 expression in both transfected RASMs and HUVECs. The effect of the steroids on PAI-1 expression in RASM is abolished by mutation of the human PAI-1 promoter in the region of a putative GRE. Studies in patients undergoing selective adrenal vein sampling confirm the relevance of these findings in humans and suggest a potential mechanism for recently reported favorable effects of aldosterone receptor antagonism on cardiovascular mortality.
